ArticleBMJ open2025
Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOveractive bladder (OAB) is a condition characterised by urinary urgency, often accompanied by frequency and nocturia. Antimuscarinics and β3 receptor agonists are first-line therapies that improve urinary symptoms and the quality of life. For insufficient antimuscarinic response, options include dose increase, switching medications or combination therapy. However, evidence for these strategies, especially combinations with vibegron, is limited and needs further study. METHODS AND ANALYSIS: The study is designed as a randomised, open-label, parallel-group, multicentre trial conducted in Japan. A total of 110 patients with OAB who met the OAB criteria and did not respond adequately to the initial 4-week antimuscarinic treatment will be randomised in a 1:1 ratio into two groups: an add-on group in which vibegron 50 mg/day is added to the current antimuscarinic drug and a switch group in which the current antimuscarinics are discontinued and replaced with vibegron 50 mg/day. The primary endpoint is the intergroup comparison of changes in daily urinary frequency between the add-on group and the switch group at 12 weeks after the initiation of protocol treatment. The primary analysis aims to confirm the non-inferiority of the switch group compared with the add-on group using a Bayesian mixed model for repeated measures. Non-inferiority will be confirmed if the posterior probability that the difference in the change in urinary frequency at 12 weeks between the two groups falls within the non-inferiority margin of one-time is 80% or greater. ETHICS AND DISSEMINATION: The trial has been reviewed and approved by the Institute of Science Tokyo Certified Clinical Research Review Board (approval number: NR2024-001). Participants will provide informed consent to participate before taking part in the study. Results will be reported in a separate publication. TRIAL REGISTRATION NUMBER: Japan Registry of Clinical Trials (jRCT) (jRCTs031240134).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.